Core A will focus on biological evaluation of extracts, chromatographic fractions, and pure isolates prepared by all of the Projects within the Program in order to help prioritize subsequent biological and chemical work. This strategy of using bioassay-guided isolation will afford us the opportunity to pursue biological activity within complex mixtures. Extracts found active by Core A will be further purified by Projects 1-3 (OSU, UIC, and UNCG, respectively) and the pure isolates will be sent to us for further analysis. Promising pure compounds will ultimately be further tested in animal models to assess efficacy and toxicity. Mechanism of action studies will be conducted to study the molecular pharmacology of pure compounds with the most favorable therapeutic indices. The Director of Core A has well-established collaborations with all ofthe Project Leaders and Core Directors of this Program Project and has previously employed a variety of assays for natural product drug discovery. Our ongoing working relationships with other Projects and Cores and our ability to develop new biological assays as needed will assure that Core A is fully integrated in the program project and serves all projects therein.
The Specific Aims for Core A are to (1) conduct cell-based assays on extracts and fractions provided by each Program. These assays will score the activity of specific molecular targets including inhibition of histone deacetylase (HDAC) or the 20S proteasome. We will work with Core C to determine the most active fractions and with the Program Leaders to decide which fractions will serve as source material for compound isolation.
Our second aim i s to test pure compounds in cell-free molecular target (HDAC &proteasome) assays to confirm activity and identify the most promising leads for in vivo studies.
Our third aim i s to assess the activity of our most promising active pure compounds in vivo. Before our animal studies are conducted, Core B will develop analytical assays, assess solubility, prepare appropriate formulations as needed and conduct preliminary pharmacokinetic and toxicity experiments. Based on data from these studies, we will work with Core B to establish the optimal formulation and dosing schedule for hollow fiber or tumor xenografts studies in immunodeficient mice. Further pharmacological studies will be performed on those pure compounds that prove to be effective anticancer agents with limited toxicity in mice. The biological assays outlined in this Core, used in concert with Cores B and C, will provide a solid foundation of support for all the Projects within the program and our industrial partner, Eisai, Inc.

Public Health Relevance

The overarching goal of this Program Project is to isolate novel agents from natural sources for the treatment of cancer. The role of Core A is to provide biological testing using a variety of molecular, cellular and animal based systems to identify promising leads for further development. Core A will obtain materials for testing from each of the three Programs, work with Core C on statistical analysis, identify leads that Core B can modify to enhance activity and Eisai, Inc can further develop for translation into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA125066-06A1
Application #
8608730
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (O1))
Project Start
2006-12-01
Project End
2019-04-30
Budget Start
2014-06-06
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$244,426
Indirect Cost
$69,934
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sica, Vincent P; Rees, Evan R; Raja, Huzefa A et al. (2017) In situ mass spectrometry monitoring of fungal cultures led to the identification of four peptaibols with a rare threonine residue. Phytochemistry 143:45-53
Henkin, Joshua M; Sydara, Kongmany; Xayvue, Mouachanh et al. (2017) Revisiting the linkage between ethnomedical use and development of new medicines: A novel plant collection strategy towards the discovery of anticancer agents. Journal of medicinal plant research 11:621-634
Paguigan, Noemi D; Al-Huniti, Mohammed H; Raja, Huzefa A et al. (2017) Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites. Bioorg Med Chem 25:5238-5246
Wang, Jiang; Zhu, Xiaohua; Kolli, Shamala et al. (2017) Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 139:187-192
Chen, Wei-Lun; Ren, Yulin; Ren, Jinhong et al. (2017) (+)-Strebloside-Induced Cytotoxicity in Ovarian Cancer Cells Is Mediated through Cardiac Glycoside Signaling Networks. J Nat Prod 80:659-669
Paguigan, Noemi D; El-Elimat, Tamam; Kao, Diana et al. (2017) Enhanced dereplication of fungal cultures via use of mass defect filtering. J Antibiot (Tokyo) 70:553-561
Ren, Yulin; Chen, Wei-Lun; Lantvit, Daniel D et al. (2017) Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity. J Nat Prod 80:648-658
Acuña, Ulyana Munoz; Curley Jr, Robert W; Fatima, Nighat et al. (2017) Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer Cells. Anticancer Res 37:1617-1623
Ren, Yulin; Gallucci, Judith C; Kinghorn, A Douglas (2017) An Intramolecular CAr-H•••O=C Hydrogen Bond and the Configuration of Rotenoids. Planta Med 83:1194-1199
Brooks, Wilson C; Paguigan, Noemi D; Raja, Huzefa A et al. (2017) qNMR for profiling the production of fungal secondary metabolites. Magn Reson Chem 55:670-676

Showing the most recent 10 out of 126 publications